EDITOR'S PICKS

More>>
LATEST MOST VIEWED: LAST ONE YEAR MOST VIEWED: LAST TWO YEARS MOST DOWNLOADED
  • image
    Original Article| Open Access

    Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation

    Eric M. Wu, Linda L. Wong, Brenda Y. Hernandez, Jun-Fang Ji, Wei Jia, Sandi A. Kwee, Sumodh Kalathil

    Aim: Worldwide, hepatocellular cancer (HCC) is the fourth leading cause of cancer death and occurs 3 times more commonly in males than females. Current surveillance practices do not fully address gender differences in HCC. Methods: Clinical characteristics and survival were compared between males... Read more

    Hepatoma Res 2018;4:66. | doi:10.20517/2394-5079.2018.87
    Published on: 18 Oct 2018  | Viewed:0  | Downloaded:0
    +HTML| PDF
  • image
    Original Article| Open Access

    Endolymphatic immunotherapy for advanced hepatocellular carcinoma: an update of our experience

    Marialuisa Lugaresi, Yuval Katz, Riccardo Bertelli, Noa Ruhrman, Lorenza Puviani, Giuseppe Cavallari, Caterina De Vinci, Giancarlo Pizza, Bruno Nardo

    Aim: We report an update of our experience on endolymphatic immunotherapy in patients with advanced hepatocellular carcinoma (HCC) not eligible for surgery. Methods: From 2003 to 2009 we enrolled 39 patients with advanced HCC not suitable for surgery. Patients underwent monthly endolymphatic... Read more

    This article belongs to the Special Issue Management of Hepatocellular Carcinoma Hepatoma Res 2018;4:67. | doi:10.20517/2394-5079.2018.88
    Published on: 18 Oct 2018  | Viewed:0  | Downloaded:0
    +HTML| PDF
  • image
    Review| Open Access

    New and old biomarkers of hepatocellular carcinoma

    Georgios Zacharakis, Ahmad Aleid, Khaled K Aldossari

    Hepatocellular carcinoma (HCC) is a significant cause of mortality in patients with chronic liver disease around the world. Development of biomarkers for early HCC detection is a primary public health goal to decrease mortality. The ideal biomarkers should be highly sensitive and specific for... Read more

    This article belongs to the Special Issue Management of Hepatocellular Carcinoma Hepatoma Res 2018;4:65. | doi:10.20517/2394-5079.2018.76
    Published on: 17 Oct 2018  | Viewed:36  | Downloaded:0
    +HTML| PDF
  • image
    Review| Open Access

    HCV elimination: breaking down the barriers to prison based care

    Timothy Papaluca, Alexander Thompson

    Hepatitis C virus (HCV) remains a major public health threat worldwide, responsible for 500,000 deaths annually; hepatocellular carcinoma (HCC) remains one of the major causes of HCV-related mortality. The global prevalence of HCV is approximately 1.0%, and in developed countries, injecting drug... Read more

    This article belongs to the Special Issue What More We can do on Hepatitis C? Hepatoma Res 2018;4:64. | doi:10.20517/2394-5079.2018.53
    Published on: 17 Oct 2018  | Viewed:31  | Downloaded:0
    +HTML| PDF
  • image
    Review| Open Access

    Alpha-fetoprotein as a predictor of hepatocellular carcinoma recurrence following liver transplantation

    Evangelia M. Fatourou, Abid R. Suddle, Michael A. Heneghan

    Alpha-fetoprotein (AFP) has been increasingly recognised as a valuable marker in predicting HCC recurrence post-liver transplantation. Moreover, its secretion has been associated with poor histological tumour characteristics as it reflects an aggressive tumour biological behaviour. This review... Read more

    This article belongs to the Special Issue Management of Hepatocellular Carcinoma Hepatoma Res 2018;4:63. | doi:10.20517/2394-5079.2018.62
    Published on: 10 Oct 2018  | Viewed:253  | Downloaded:18
    +HTML| PDF
  • image
    Review| Open Access

    Liver transplantation for hepatocellular carcinoma - non-cancer factors and implications for improving outcome beyond standard tumor criteria

    Arno Kornberg, Martina Schernhammer

    Liver transplantation (LT) is recognized as best treatment option in patients with early hepatocellular cancer (HCC) in underlying liver cirrhosis. Apart from tumor size and number implemented in the Milan criteria, which are current worldwide standards for patient selection, several biological... Read more

    This article belongs to the Special Issue Management of Hepatocellular Carcinoma Hepatoma Res 2018;4:60. | doi:10.20517/2394-5079.2018.86
    Published on: 29 Sep 2018  | Viewed:262  | Downloaded:12
    +HTML| PDF
  • image
    Original Article| Open Access

    Quantitative hepatitis B surface antigen in predicting recurrence of hepatitis B-related hepatocellular carcinoma after liver transplantation

    James Fung, Danny Ka-Ho Wong, Yasuhito Tanaka, Regina Lo, Tiffany Wong, Kenneth Siu-Ho Chok, Albert Chi-Yan Chan, Tan-To Cheung, Wing-Chiu Dai, Kelvin Ng, Kevin Ng, Man Kwan, Irene Ng, Wai-Kay Seto, Ching-Lung Lai, Man-Fung Yuen, Chung-Mau Lo

    Aim: Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) for chronic hepatitis B (CHB) can be associated with reappearance of hepatitis B surface antigen (HBsAg). The current study determined the significance of HBsAg qualitatively and quantitatively using a highly... Read more

    Hepatoma Res 2018;4:62. | doi:10.20517/2394-5079.2018.92
    Published on: 29 Sep 2018  | Viewed:307  | Downloaded:13
    +HTML| PDF
  • image
    Original Article| Open Access

    Novel diagnosis and therapy for hepatoma targeting HBV-related carcinogenesis through alternative splicing of FIR (PUF60)/FIRΔexon2

    Kazuyuki Matsushita, Tyuji Hoshino

    Aim: Disturbed alternative splicing of far upstream element-binding protein-interacting repressor (FIR) was found to be unable to repress c-Myc transcription and so it might be important for suppressing tumor development. FIR is a splicing variant of poly (U)-binding-splicing factor (PUF60), and... Read more

    This article belongs to the Special Issue Management of Hepatocellular Carcinoma Hepatoma Res 2018;4:61. | doi:10.20517/2394-5079.2018.81
    Published on: 29 Sep 2018  | Viewed:352  | Downloaded:15
    +HTML| PDF
  • image
    Review| Open Access

    Role of the contrast-enhanced ultrasoud in the diagnosis of HCC in cirrhotic liver

    Francesco Loria, Antonello Parlati, Giuseppe Loria, Luciano Frosina, Giuseppe Crea, Salvatore Basile, Caterina Alessio, Giuseppe Di Leo, Adele De Caridi, Vittorio Maschio, Nicola Zizzi, Orazio Trapuzzano, Salvatore Giuseppe Galea

    The development of second generation ultrasound (US) contrast-medium and specific imaging techniques with dedicated softwares, allows to observe the liver perfusion in real time, becoming an useful and less invasive method to describe precisely the vascularization of hepatic lesions. This... Read more

    This article belongs to the Special Issue New Insights in Liver Cancer Hepatoma Res 2018;4:59. | doi:10.20517/2394-5079.2018.75
    Published on: 28 Sep 2018  | Viewed:302  | Downloaded:21
    +HTML| PDF
  • image
    Review| Open Access

    Staging of hepatocellular carcinoma

    Sedat Karademir

    Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths in the world. In contrast to other cancers, survival of patients with HCC is determined by the extent of the tumor in addition to underlying liver disease and its functional reserve. From risk factors to management, HCC... Read more

    This article belongs to the Special Issue Management of Hepatocellular Carcinoma Hepatoma Res 2018;4:58. | doi:10.20517/2394-5079.2018.40
    Published on: 26 Sep 2018  | Viewed:215  | Downloaded:10
    +HTML| PDF
+MoreView all articles
Subscribe

To receive email updates about the journal, please subscribe here.

News More>>
Partners
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.